Financial Contrast: Masimo (NASDAQ:MASI) versus Endonovo Therapeutics (OTCMKTS:ENDV)

Masimo (NASDAQ:MASI) and Endonovo Therapeutics (OTCMKTS:ENDV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Masimo and Endonovo Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0	5	2	0	2.29
Endonovo Therapeutics	0	0	0	0	N/A

Masimo presently has a consensus price target of $134.29, suggesting a potential downside of 8.56%. Given Masimo’s higher possible upside, equities research analysts clearly believe Masimo is more favorable than Endonovo Therapeutics.

Institutional and Insider Ownership

86.0% of Masimo shares are owned by institutional investors. 9.7% of Masimo shares are owned by company insiders. Comparatively, 5.6% of Endonovo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Masimo has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of -1.42, suggesting that its share price is 242% less volatile than the S&P 500.

Profitability

This table compares Masimo and Endonovo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Masimo	3.98%	13.77%	5.98%
Endonovo Therapeutics	-1,717.21%	N/A	-408.63%

Earnings & Valuation

This table compares Masimo and Endonovo Therapeutics’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$2.05 billion	3.79	$81.50 million	$1.51	97.25
Endonovo Therapeutics	$140,000.00	7.37	-$18.48 million	N/A	N/A

Masimo has higher revenue and earnings than Endonovo Therapeutics.

Summary

Masimo beats Endonovo Therapeutics on 10 of the 11 factors compared between the two stocks.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.